secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001104659-22-126067
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma CFO Andrew Hindman to depart Dec 31; Aziz Sawaf named successor
--------------------------------------------------------------------------------

- Andrew Hindman, SVP and CFO, will leave on December 31, 2022.
- Aziz Sawaf appointed CFO effective Jan 1, 2023; previously VP of Finance since Oct 2021.
- Sawaf joined Theravance in 2014; prior roles at Gilead Sciences, Amgen, and consulting.
- Sawaf holds CFA charter, MBA from USC, and MBEE from Johns Hopkins University.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/0001104659-22-126067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465922126067/tm2232423d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-126067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer